HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 1,129-1,140 of 4,505
Drug study icon
Active Not RecruitingNCT02926859

Enhancing Recovery in Early Schizophrenia

Official study title

Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol vs. Placebo as an add-on to an Individualized Antipsychotic Treatment

This study is no longer accepting new participants.

Multiple locations, including Mannheim
SchizophreniaMedication studyAges 18–65
Countries
Germany
Sponsor
Central Institute of Mental Health, Mannheim
Drug study icon
CompletedNCT00236353

Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder

Official study title

An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–65
Countries
Sponsor
Janssen, LP
Other study type icon
CompletedNCT05257720

Evaluation of the Role of Neurodegeneration in Schizophrenia

Official study title

Evaluation of the Role of Neurodegeneration in Treatment Resistant Schizophrenia With GFAP and S100B

This study has finished and is no longer accepting participants.

In Istanbul
SchizophreniaObservational studyAges 18–65
Countries
Türkiye
Sponsor
Istanbul Saglik Bilimleri University
Drug study icon
CompletedNCT00236548

Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which adults with Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection

Official study title

An Open-label Evaluation of the Utility of the RISPERDAL CONSTA Treatment Guidebook During Transition of Adult Patients With Schizophrenia or Schizoaffective Disorder to RISPERDAL CONSTA (Risperidone) Treatment Over Three Months in the Community Mental Health Center (CMHC) Setting

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–65
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
WithdrawnNCT00916201

Evaluation Study of New Compounds With Potential Use in Schizophrenia

What is this study about?

Researchers are comparing intranasal Insulin, Cannabidiol CR and URB597 to find out how the approaches affect depression symptoms in healthy volunteers.

This study was withdrawn before enrollment.

In Mannheim
SchizophreniaMedication studyAges 18–65
Countries
Germany
Sponsor
Central Institute of Mental Health, Mannheim
Device study icon
CompletedNCT05438160

Exploratory Study of a Digital Therapeutics in People With Schizophrenia

Official study title

A Multi-center, Exploratory, Single-Arm, 7-week Study to Evaluate the Feasibility and Acceptability of the Medication Tracking and Educational Components of a Clinical Learning Version of CT-155 in People With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Anaheim
SchizophreniaDevice studyAges 18–64
Countries
United States
Sponsor
Click Therapeutics, Inc.

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.